Status:
COMPLETED
Immunotherapy of the Paraneoplastic Syndromes
Lead Sponsor:
Rockefeller University
Conditions:
Paraneoplastic Syndromes
Eligibility:
All Genders
14+ years
Phase:
NA
Brief Summary
We treat a subset of patients with paraneoplastic neurologic disorders, including those with Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most commonly associate...
Detailed Description
Patients may stay either in-hospital while being treated with Tacrolimus, receive treatment as an outpatient, or a combination of the two. Additionally, patients who are too sick to be treated at Rock...
Eligibility Criteria
Inclusion
- Patients diagnosed with Paraneoplastic Disorder
Exclusion
- Metastasis (spread) of cancer to brain, History of additional active malignancy other than non-melanoma skin cancer, History of Hepatitis B, Hepatitis C, HIV or Syphilis.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00378326
Start Date
April 1 2006
End Date
May 1 2014
Last Update
September 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockefeller University Hospital
New York, New York, United States, 10021